GranNEX® is Mycenax’s filgrastim, the biosimilar version of Neupogen®, and the recombinant human granulocyte colony-stimulating factor, G-CSF. It can stimulate the growth of white cell.
Filgratim® is indicated for neutropenia, as the adjunct therapy for cancer chemotherapy and AIDS therapy. The development of GranNEX® followed the regulatory pathway of biosimilar, with high biosimilarity to its reference product, and complied with the requirements of European Medicine Agency. This project is granted by Ministry of Economic Affairs (MOEA) and selected as the critical path project by Center for Drug Evaluation (CDE) in Taiwan.
Mycenax has completed GranNEX®’s pre-clinical development, and will focus on application of new delivery system or new formulation for patient’s ease of using GranNEX®.